Validating Novel Biomarkers Relevant To Major Depression
Funder
National Health and Medical Research Council
Funding Amount
$515,550.00
Summary
Depression prevention and treatment are public health priorities; therefore, it is critical to improve and personalise treatments, which can only be achieved by advancing knowledge of its underlying biology. This research project will contribute to validating potentially relevant genes for MDD risk or antidepressant response and to provide the scientific foundation for future strategies to test their products as MDD biomarkers in the clinical setting.
Deep Brain Stimulation In The Treatment Of Severe Depression
Funder
National Health and Medical Research Council
Funding Amount
$1,008,087.00
Summary
Some patients with depression fail to respond to a variety of standard treatments and in this group, deep brain stimulation (DBS) is being evaluated as an alternative treatment option. This study will investigate the use of DBS applied to a novel brain target site in patients with highly treatment refractory depression.
Providing Evidence For The Primary Prevention Of The High-prevalence Mental Disorders In Men: The Role Of Diet In The Aetiology Of Depression, Anxiety, And Psychological Distress
Funder
National Health and Medical Research Council
Funding Amount
$300,862.00
Summary
Depression is predicted to become the second-most common cause of disability in the world by 2020, despite the increased energy devoted to recognition and treatment. This study will examine the association between diet quality and depressive and anxiety disorders in men, to identify to what extent diet quality is related to the risk for and/or course of these illnesses.
AusGDB-Depression: An Australian Genetic Database Study Of Functional Genetic Variants And Environmental Factors In Major Depression
Funder
National Health and Medical Research Council
Funding Amount
$620,486.00
Summary
Major depression is the leading cause of disability in Australia, but its causes are unknown. Despite a significant role of genes in this disorder and many genetic studies, researchers have not been able to identify the genes that increase the risk for this disorder. In this project, we will identify, characterize and use genetic functional variants and environmental factors to create a way to predict diagnosis of this disorder.
Diet As A Therapeutic Target In Depression: A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$498,564.00
Summary
Depression is predicted to become the second-most common cause of disability in the world by 2020. While there is now compelling new evidence to suggest that diet plays an important role in the risk for and the genesis of depression, there are no existing data regarding the impact of dietary improvement on existing depressive illness. The aim of the proposed study is to answer the critically important and frequently asked question "If I improve my diet, will my mental health improve?"
Differential Changes In Cortical Tumour Necrosis Factor Signalling In Mood Disorders And Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$642,078.00
Summary
Changes in inflammation-related pathways contribute to the symptoms of psychiatric disorders and tumour necrosis factor ? (TNF) is a protein central to regulating theses pathways. We have now shown that changes in pathways regulated by TNF are present in the brains of people with schizophrenia and mood disorders. This means that the symptoms experienced by those with the different disorders may be linked to differential changes in TNF-regulated pathways in the brain.
Neural Predictors Of Treatment Response In Youth Depression
Funder
National Health and Medical Research Council
Funding Amount
$519,596.00
Summary
Depression is the single greatest cause of disability and morbidity in young people. In order to reduce its substantial burden on individuals and society, there is a need to optimise the early provision of existing treatments. In this study, we will use cutting-edge neuroimaging technology to identify “biomarkers” in the brain that will help to more accurately determine which available treatments are likely to be most effective and safe for an individual patient.
The Unique Nature Of Gamma Delta T Cell Recognition Resolved Through Interaction With H2-Q10
Funder
National Health and Medical Research Council
Funding Amount
$699,031.00
Summary
The liver is important for both digestion and immunity. Given these opposing functions, the liver must exert control points that prevent the immune system from recognising food products. We have now identified a new molecular target that controls the development of immune cells in the liver.
Unraveling The Link Between HLA B27 And Autoimmunity
Funder
National Health and Medical Research Council
Funding Amount
$746,102.00
Summary
Ankylosing spondylitis and related diseases cause significant morbidity in up to 0.25% of the population. Current treatments have limited efficacy and often debilitating side effects. More targeted peptide antigen based therapies will have fewer side effects and would be of major clinical importance to this group of diseases. This project seeks to identify peptide antigens that could be used in targeted immunotherapy. We also seek to understand how some of the idiosyncratic properties of HLA B27
The liver is an important organ in terms of immune responses. Owing to its exposure to many antigens, it is required to maintain a form of immune tolerance. This ensures that overt immune responses which would damage the liver do not occur. One means by which tolerance occurs is through silencing killer cells through the regulation of molecules of Major Histocompatibility Complex (MHC). This project will explore the role of a soluble form of MHC which is expressed only in the liver.